

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number
WO 2005/002606 A1

(51) International Patent Classification⁷: A61K 35/74, (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/NO2004/000204

(22) International Filing Date: 2 July 2004 (02.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 20033082 4 July 2003 (04.07.2003) NO

(71) Applicants (for all designated States except US): THIA MEDICA AS [NO/NO]; c/o Jon Skorve, Haukeland Universitetssykehus, N-5021 Bergen (NO). NORFERM DA [NO/NO]; P.O. Box 8005, N-4068 Stavanger (NO).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BERGE, Rolf [NO/NO]; Tjørnhaugen 50, N-5062 Bønes (NO). KLEPPE, Gunnar [NO/NO]; Kong Haralds gt 5, N-4044 Hafrsfjord (NO).

(74) Agent: AS BERGEN PATENTKONTOR; Strandgaten 198, P.O. Box 1998, Nordnes, N-5817 Bergen (NO).

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/002606 A1

(54) Title: USE OF A SINGLE-CELL PROTEIN MATERIAL

(57) Abstract: The present invention relates to the use of a single-cell protein material (SCP). The SCP material lowers the concentration of cholesterol in plasma, and triglycerides in the liver. SCP also induces a favourable change in the fatty acid pattern, and lowers the concentration of homocysteine in plasma. A preferable embodiment of the invention relates to the use of SCP as an anti-atherogenic and cardio protective agent, either given as a pharmaceutical or as nutritional composition, e.g. as a functional food.